This event will focus on the latest progress in precision genome editing, novel delivery vectors, allogeneic cell therapies and the journey from laboratory research to clinical application, offering ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...

Regulatory agencies are open to changes within the review process which means the uptake of CAR T-cell therapy will change the landscape itself. This is especially true with large-scale ...

We can do better. We can build a system that provides coordinated high-quality care to every patient who needs it.

There are 20 cell and gene therapies on Europe's market versus 43 in the U.S. Find out more about this ecosystem.

Growth Drivers of The Gene Therapy Industry As per IMARC, the US gene therapy market size has been pegged at US$1,312.2 million in 2024. The market should reach US$3,697.8 million by 2033.

Hiroyuki Nakai, M.D., Ph.D., OHSU School of Medicine Distinguished ... [highly specialized cells] in the kidney, the two important target cell types for gene therapy, and while there is a ...

A preview of Nebraska Medicine's Innovation ... approved a separate gene therapy for hemophilia A last year. The agency also has approved two gene therapies for sickle cell disease, another ...